Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

San Diego startup DTx Pharma, which is developing technology for delivering RNA-based therapies to hard-to-treat diseases, has been acquired by drug giant Novartis for $500 million. Founded in 2017, ...

SAN FRANCISCO (AP) _ The biotechnology field is littered with the debris of would-be miracle cures. These days, the buzz is building around a technology called ``RNA interference,'' whose legions of ...

New York, May 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global RNA Interference Technology Market - Premium Insight, Competitive News Feed Analysis, Company ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The latest biotechnology company hoping to get genetic ...

Lethal and rescuer genes are defined as genes that when inactivated result in cell death or enhanced cell growth, respectively. The ability to identify these genes in large-scale automated screening ...

The firm's antisense oligonucleotide, or ASO, technology faces strong competition from RNA interference technology emerging from Alnylam, Arrowhead, and Novo Nordisk (Dicerna), as well as gene editing ...

For decades, the central dogma of molecular biology—DNA makes RNA, RNA makes protein, protein makes phenotype—was the guiding framework for understanding inheritance and disease. This model explained ...